Search Results - "Del Muro, J García"

Phase II study with the combination of gemcitabine and DTIC in patients with advanced soft tissue sarcomas by LOSA, R, FRA, J, ESCUDERO, P, ESTEBAN, E, BUESA, José M, LOPEZ-POUSA, A, SIERRA, M, GOITIA, A, UNA, E, NADAL, R, GARCIA DEL MURO, J, GION, M, MAUREL, J

“…Based on the promising results of a Phase I study with a combination of gemcitabine and DTIC performed in advanced soft tissue sarcoma (ASTS) patients, and due…”
Get full text

Phase II clinical trial with pegylated liposomal doxorubicin (CAELYX®/Doxil®) and quality of life evaluation (EORTC QLQ-C30) in adult patients with advanced soft tissue sarcomas A study of the Spanish Group for Research in Sarcomas (GEIS) by Poveda, A., López-Pousa, A., Martín, J., Del Muro, J. García, Bernabé, R., Casado, A., Balañá, C., Sanmartín, O., Menéndez, M. D., Escudero, P., Cruz, J., Belyakova, Elena, Menéndez, D., Buesa, J. M.

“…Background: Pegylated liposomal doxorubicin (PLD), a formulation with pharmacokinetic differences with respect to doxorubicin (DXR), might benefit patients…”
Get full text

Phase II Trial of Doxorubicin Plus Escalated High-Dose Ifosfamide in Patients With Advanced Soft Tissue Sarcomas of the Adult: A Study of the Spanish Group for Research on Sarcomas (GEIS) by Buesa, J.M, Garcia del Muro, J, Cruz, J, Montalar, J, Escudero, P, Martin, J, Maurel, J, Lopez-Pousa, A, de las Penas, R, Casado, A

“…Background. To explore the tolerance and the activity of high-dose ifosfamide (IFOS) combined with doxorubicin (DXR) at 50 mg/m(2) every 4 weeks in patients…”
Get full text

Phase II trial of first-line high-dose ifosfamide in advanced soft tissue sarcomas of the adult: A study of the Spanish Group for Research on Sarcomas (GEIS) by Buesa, J. M., López-Pousa, A., Martín, J., Antón, A., García del Muro, J., Bellmunt, J., Arranz, F., Valentí, V., Escudero, P., Menéndez, D., Casado, A., Poveda, A.

“…Background: The agent Ifosfamide (IFOS) is active against soft tissue sarcomas (STS), and patients who progress to IFOS at doses ≤ 10 g/m2 show remissions when…”
Get full text

Phase I II trial of doxorubicin and fixed dose-rate infusion gemcitabine in advanced soft tissue sarcomas: a GEIS study by LOPEZ-POUSA, A, LOSA, R, MARTINEZ-TRUFERO, J, ESTEBAN, E, BUESA, J. M, MARTIN, J, MAUREL, J, FRA, J, SIERRA, M, CASADO, A, GARCIA DEL MURO, J, POVEDA, A, BALANA, C

“…The aim of the study was to determine the dose-limiting toxicity and maximum tolerated dose of a first-line combination of doxorubicin and gemcitabine in adult…”
Get full text

Anti-Hu antibodies in patients with small-cell lung cancer: association with complete response to therapy and improved survival by Graus, F, Dalmou, J, Reñé, R, Tora, M, Malats, N, Verschuuren, J J, Cardenal, F, Viñolas, N, Garcia del Muro, J, Vadell, C, Mason, W P, Rosell, R, Posner, J B, Real, F X

“…Anti-Hu antibodies (HuAb) recognize antigens expressed by neurons and small-cell lung cancer (SCLC). High titers of HuAb were initially reported in serum from…”
Get more information

Activity of doxorubicin after high-dose ifosfamide in adult patients with advanced soft tissue sarcoma: A study of the Spanish Group for Research on Sarcomas (GEIS) by Buesa, J. M., Fra, J., Antón, A., López-Pousa, A., Martín, J., García del Muro, J., Escudero, P., Casado, A., Poveda, A.

Get full text

CDC group IV c-2 infection in a stem cell transplant recipient by Arance, A, Montes, A, Cisnal, M, Mesía, R, Falo, C, García del Muro, J, Germà, J R

“…Patients undergoing high-dose chemotherapy for cancer are at a high risk of infections caused by unusual microorganisms. Previous chemotherapy, use of…”
Get full text

789P A differential gene expression signature identifies a population of stage I testicular non-seminomatous germ cell tumours (NSGCT) at high risk of relapse by Galvez-Carvajal, L., Sánchez-Muñoz, A., Álvarez, M., Alba Linero, E., del Rey, M., Garrido, A., Santoja, Á., Moya, A., Montes, J., Chica-Parrado, M.R., Sáez, M.I., Aparicio, J., González-Billalabeitia, E., Terrasa Pons, J., Méndez, M.J., Luengo, M., García del Muro, J., Pascual, J., Alba, E.

Get full text

Positron emission tomography-computed tomography in tumors of the locomotor apparatus by Gámez Cenzano, C, Sabaté Llobera, A, Narváez García, J A, Rodríguez Bel, L, García del Muro, F J

“…Positron emission tomography/computed tomography (PET/CT) is a hybrid imaging technique that combines the anatomic information from CT with the metabolic…”
Get more information

Prognostic value of pathologic variables and mutations type in patients with complete surgical resection of gastrointestinal stromal tumors (GIST). A GEIS study by Martin, J., Poveda, A., Llombart-Bosch, A., Ramos, R., García Del Muro, J., Martinez, J., De Juan, A., Maurel, J., Losa, F., Buesa, J. M.

“…Abstract only…”
Get full text

Prognostic value of pathologic variables and mutations type in patients with complete surgical resection of gastrointestinal stromal tumors (GIST). A GEIS study by Martin, J., Poveda, A., Llombart-Bosch, A., Ramos, R., García Del Muro, J., Martinez, J., De Juan, A., Maurel, J., Losa, F., Buesa, J. M.

“…Abstract only…”
Get full text

Phase II Clinical Trial With Pegylated Liposomal Doxorubicin (CAELYX(R)/Doxil(R)) and Quality of Life Evaluation (EORTC QLQ-C30) in Adult Patients With Advanced Soft Tissue Sarcomas: A study of the Spanish Group for Research in Sarcomas (GEIS) by Poveda, A, López-Pousa, A, Martín, J, Del Muro, J García, Bernabé, R, Casado, A, Balañá, C, Sanmartín, O, Menéndez, M D, Escudero, P, Cruz, J, Belyakova, Elena, Menéndez, D, Buesa, J M

“…Pegylated liposomal doxorubicin (PLD), a formulation with pharmacokinetic differences with respect to doxorubicin (DXR), might benefit patients with advanced…”
Get full text

Primary germ cell tumors of the central nervous system by Losa, F, García del Muro, J, Germà, J R

“…Germ cell tumors located in the central nervous system represent less than 4% of the intracranial tumors and affect primarily children and young adults. They…”
Get more information

Time dependence of critical deletions as prognostic factor for relapse-free survival (RFS) in localised GIST. A Spanish Group for Sarcoma Research (GEIS) study by Martin, J., Gutierrez, A., Garcia del Muro, J., Maurel, J., Gonzalez de Sande, L. M., Martinez, J., De Juan, A., Lainez, N., Losa, F., Poveda, A.

“…Abstract only…”
Get full text

Doxorubicin (DXR) and prolonged infusion gemcitabine (GMC) as first-line treatment in advanced soft tissue sarcomas (STS). A phase II trial of the Spanish Group for Research in Sarcomas (GEIS) by Lopez-Pousa, A., Buesa, J., Casado, A., Garcia Del Muro, J., Poveda, A., Maurel, J., Martin, J., Balaña, C., Martinez, J.

“…Abstract only…”
Get full text

Doxorubicin (DXR) and prolonged infusion gemcitabine (GMC) as first-line treatment in advanced soft tissue sarcomas (STS). A phase II trial of the Spanish Group for Research in Sarcomas (GEIS) by Lopez-Pousa, A., Buesa, J., Casado, A., Garcia Del Muro, J., Poveda, A., Maurel, J., Martin, J., Balaña, C., Martinez, J.

“…Abstract only…”
Get full text

Bacteremial pneumonia caused by Moraxella catarrhalis in a neutropenic patient by Rosón, B, Santín, M, García del Muro, J, Carratalá, J

Get more information

Preoperative chemoradiotherapy (CHT-RDT) in locally advanced rectal cancer (RC). Preliminary results by Majem, M., Navarro, M., Urruticoechea, A., Perez, F.J., Cambray, M., Del Rio, C., Garcia del Muro, J., Germa, J.R.

Get full text

Phase II clinical trial with pegylated liposomal doxorubicin by Poveda, A, Lopez-Pousa, A, Martin, J, Del Muro, J. Garcia, Bernabe, R, Casado, A, Balana, C, Sanmartin, O, Menendez, M.D, Escudero, P, Cruz, J, Belyakova, Elena, Menendez, D, Buesa, J.M

Get full text